Ahmed Yaqinuddin^1*, Ayesha Rahman Ambia¹, Hind Kazkaz¹, Maha bint Mishari AlSaud¹, Khaled Alkattan¹ and Junaid Kashir^2
*Correspondence: Ahmed Yaqinuddin, Alfaisal University, Kingdom of Saudi Arabia, Email:

Received: 25-Feb-2021 Accepted Date: Mar 16, 2021 ; Published: 25-Mar-2021

Keywords

COVID-19; SARS-CoV-2; Vaccines; Bacil- li-Calmette-Guerin (BCG); Polio vaccine (OPV)

Introduction

The current COVID-19 outbreak in December 2019 caused a devastating ripple of events in the international community caused by SARS-CoV2, a zoonotic coronavirus that has increas- ingly become difficult to control. There is thus a pressing need to improve our understanding of the immunology of this dis- ease to develop treatments and preventative measures against this phenomenon.^1-3

Coronaviruses (CoV) are enveloped, single stranded positive sense RNA (ssRNA) belonging to the Coronavirinae family, of which seven are known to infect humans.3 Human SARS-CoV-2 exhibits a classical flu-like clinical presentation in more than 80% of patients who have mild to moderate and self-limiting disease, with an estimated incubation period of anywhere between 2-14 days. Asymptomatic presentation has also been recorded in a significant number of individuals, underlying increases in unsus- pected transmission.⁴ SARS-CoV-2 enters target cells via a spike protein (S). An interesting feature of S is the mediation of cell fu- sion and formation of syncytia, used to elude immune cells.3 The helical envelope of the SARS-CoV-2 also contains the matrix pro- tein (M), nucleocapsid (N), and envelope protein (E). SARS-CoV- 2 has been observed to enter the respiratory epithe-lium by means of the angiotensin converting enzyme 2 (ACE2) receptors, also present in the gastric endothelium, potentially explaining the diarrhea and nausea symptoms of COVID-19. A¬CE2 catalyzes the conversion of angiotensin I to angiotensin II, contributing towards maintenance of fluid and electrolyte homeostasis, and entry also interestingly seems to be aided by two host proteases ADAM17 and TMPRSS2.5 Viral load and repeated expo- sure to the virus are important factors determining disease severity, with clinical deterioration usually observed at the end of the second week following development of a cytokine storm, causing disseminated intravascular coagulation (DIC). Many aspects of severe COVID-19 infection are unique, rarely occurring in other respiratory viral infections, including severe lymphopenia and eosinopenia, extensive pneumonia and lung tissue damage, acute respiratory distress syndrome (ARDS), and multi-organ dysfunction (MOD). Marked elevation of the acute phase reactants levels like ESR, CRP, ferritin and lymphopenia are early indicators of high disease severity.^5-7

The COVID-19 vaccine landscape

As of writing this article, SARS-CoV-2 has resulted in well over 58 million global infections, a global death toll exceeding 1.3 mil- lion, and an almost unquantifiable destruction of the global econ- omy far exceeding trillions of dollars.⁸ The current pandemic has, continues to, and will further, devastate the most vulnerable in our societies; persons ≥65 years of age, persons with underlying conditions, the economically deprived, and perhaps by extension, various ethnic minorities.⁹ Thus, a monumental and herculean effort has been mounted worldwide to urgently produce a suit- able vaccine to prevent and stem COVID-19.¹⁰ Indeed, it seems to have become widely accepted that global normalcy will not return until safe and effective vaccines are available and deployed via an effective global vaccination programme.^11,12 However, considering that COVID-19 represents a new phenome- non to afflict humanity, the nature of protective immune respons- es is poorly understood, compounded further by a lack of clarity or consensus regarding mechanisms and pathogenesis of infec- tion. To this degree, despite at least 166 vaccine candidates are currently in preclinical and clinical development (Table 1), it is unclear which strategies will be most successful.¹¹ However, despite such monumental efforts, there remains a lack of consensus as to COVID-19 vaccine strate- gy.¹² The rapid pace of COVID-19 vaccine development has been enabled by several factors including existing knowledge of spike protein pathogenesis in coronaviral infection; advances allowing creation and prompt manufacture of thousands of vaccine doses; and refinement of vaccine development for stages to be conduct- ed in parallel, rather than sequentially, without increasing risks for study participants.^10-15

Potential setbacks to a newly designed COVID-19 vaccine

A number of uncomfortable truths require confrontation to view the recent advances made in the context required. Traditional- ly, the vaccine industry has long been underfunded, espousing low production capacity, difficulty in predicting infectious out- breaks, and assessing the risk to benefit ratio. Moreover, vac- cines are generally manufactured for healthy adult populations between the ages of 18 to 65 years, and do not include the pedi- atric, geriatric or immunocompromised populations – perhaps the largest population vulnerable to COVID-19. There has also been a long history of scarcity of interest in vaccine production by pharmaceutical companies.¹⁶

COVID-19 vaccine development has employed both tradition- al methods (live attenuated and inactivated vaccines), and next generation vaccines, with the latter including vaccines that are already known in the market such as DNA vaccines and nov- el vaccine techniques such as mRNA vaccines and recombinant spike protein (S) vaccine.¹⁷ Considering that the usual timeline for vaccine development is three to nine years in normal vaccine trials, most COVID-19 vaccine trials are occurring at breakneck speed (Figure 1).^10,18 While such monumental efforts have led to a number of vaccine candidates that have elicited much hope regarding effectiveness, including those from Pfizer/BioNTech, University of Oxford/Astrazeneca, Moderna/NIAID, and Sino- vac/Sinopharm/CanSino candidates, there still are concerns re- garding whether these vaccines will enable an effective response to the virus itself.^11,19

It is well accepted that drugs or biological agents will cause spe- cific side effects or adverse reactions, and utility of such agents is determined by balancing the advantageous against disadvan- tageous affects.^19,20 Current criteria, at least in the USA, limit the window to identify adverse reactions to 2 months. Adenoviral vaccine adverse effects include fever, pneumonia, diarrhoea, transient neutropenia and lymphopenia, fatigue, laboured breathing, headaches, liver damage, and fasting hyperglycae- mia. Further more significant, yet rarer, side effects include neu- ropathies, Guillain-Barré syndrome, gait disturbance, specific inflammatory conditions.²⁰ Perhaps these side effects are caused by pre-existing acquired anti-adenoviral immunity from previ- ous infections, promoting long-lived B and T cell responses and increased production of antibodies.²⁰

Some other more recent vaccine candidates against SARS-CoV-2 are also utilising more cutting-edge technologies incorporating DNA/RNA-based vaccine approaches. Such approaches utilise fragments of recombinant genetic material coding viral compo- nents (such as S), injection of which induces the body to pro- duce this antigen, inducing an immune response and memo- ry.²¹ However, while such vaccines can be rapidly designed and cheaply manufactured, there are currently no approved similar vaccines types for medical use in humans. Furthermore, such vaccines would only allow immunity against specific fragments of the virus, potentially prompting a relatively poor protective immune response requiring multiple ‘top-ups’. Then there is also the relatively low, yet still theoretically valid, possibility that such DNA/RNA fragments could be incorporated into the human genome^.21 Indeed, these and many other vaccine types are currently being considered and investigated, each specific strategy containing its own specific pros and cons which need considering (Table 2).^19,22

Hypothesis: Non-specific effects of vaccines meant for other tar- gets may prove beneficial towards preventing severe COVID-19.

Considering the various concerns surrounding the production of a COVID-19 vaccine, perhaps it would be advisable to con- sider existing strategies, utilised for a number of years with documented results and potential side effects, to aid in the bat- tle against COVID-19 and perhaps assist in interim efforts to stem the spread of this disease. Some vaccines such as the Bacil- li-Calmette-Guerin (BCG) vaccine are able to broadly stimulate the innate immune system to confer non-specific protection or effects (NSE) against disease other than tuberculosis, such as blad- der carcinoma, asthma or influenza.17 BCG confers immunity by “training” components of the innate immune system through NOD2 receptor signaling pathways in macrophages, leading to macrophage stimulation of cytokine release such as TNF-α and IL-6 against non-specific pathogens, and upregulation of toll-like receptor (TLR) ligands. Natural killer (NK) cells, another innate cell component, are also “trained” to develop an immunological memory.²³

There is considerable evidence that BCG has non-tuberculosis protective effects.²⁴ BCG may also provide non-specific protec- tion against S. aureus and C. Albicans, leading to a heightened secretion of pro-inflammatory cytokines such as IL-6, IL-1 by natural killer cells (NK cells).²⁵ Collectively, evidence suggests immune-boosting effects of BCG on COVID-19 patients, alerting the immune system to prepare against SARS-CoV2. Indeed, an increased mortality rate was observed in countries with no man- datory BCG vaccination, namely the USA.26 However, while ep- idemiological studies have shown a lack of association between a nation-wide BCG vaccination policy and decreased COVID-19 mortality, this is not entirely representative due to a of lack of ad- justment for huge differences between countries, rural or urban areas, time of pandemic start, the criteria for testing, or number of tests. Indeed, when a BCG index (the degree of national BCG vaccination) was employed, a 10.4% decrease in COVID-19 mor- tality for every 10% increase in the BCG index was observed.²⁴

Several other live attenuated vaccines including those against Measles, Mumps, and Rubella (MMR) and the Polio vaccine (OPV) also show non-specific immunity, reducing mortality, hospital stay and development of herd immunity. The mea- sles component of the MMR vaccine specifically led to NSE, in contrast to the deleterious effects of inactivated vaccines, such as diphtheria-tetanus-pertussis (DTP), that lead to increased mortality.²⁷ The beneficial effects of OPV have also been studied since the 1960’s, reducing morbidity and mortality. Such benefits have also been shown in measles, smallpox and BCG vaccine. An OPV vaccination study in 1998, Guinea-Bissau showed de- creased mortality in children under the age of five, for diseases other than polio.28 A randomized clinical trial is currently be- ing undergone in USA on “OPV as Potential Protection against COVID-19”, while milder COVID-19 symptoms in US Navy re- cruits may have been a consequence of the MMR vaccine^.29,30

Antigen sharing:

To explore potential antigen sharing, Shelly et al., [31] compared SARS-CoV-2 epitopes with OPV and BCG epitopes using pro- tein basic local alignment search tool (BLAST).^31-33 Finding a 80% similarity between SARS-CoV-2 open reading frame 7a (Orf7a) protein epitope with the human poliovirus type 3 Sabin strain epitope. Similarly, the SARS-CoV-2 nucleocapsid epitope shared an 87% similarity with part of the human poliovirus type 1 Ma- honey epitope.31 While no such direct epitope sequence match- ing was observed found between BCG and SARS-CoV-2. How- ever, such analyses only examined antigen similarity not taking into account 3D structure and subcellular localization, which are required to fully antibodies cross-reactivity.³¹

For most of these vaccines, the exact measurement of protection provided is unknown. However, it would seem indubitable that at least some level of immunity is provided. Measles-contain- ing vaccines reduce mortality by 30-86%; this reduction offered is more than the mortality caused by measles itself. A possible mechanism of action of the NSE is cross reactivity between vari- ous vaccines and antigens. An alternative hypothesis states that BCG activates T helper 1 and 17 cells polarization, T-helper cell generation, NK memory and cytokine induction.28,34 BCG had become the main vaccine to protect children against tuberculo- sis since 1924, substantiated by a clinical study showing a 40% reduction in neonatal mortality in infants that were immunized with BCG at birth.²⁸

BCG vaccine applications for COVID-19

Two mechanisms have been proposed to explain BCG’s non-spe- cific effects, namely heterologous or trained immunity. The het- erologous immunity theory proposed that BCG vaccine antigens elicit cross-reactive antibody production against other patho- gens, while the trained immunity hypothesis suggests that in- nate immune cells are ‘trained’ to develop a pro-inflammatory response following BCG stimulation.35 Indeed, derivatives of fungi and bacteria, such as BCG, Lipopolysaccharide (LPS), and Glucan, can indeed train innate immune cells, which in the case of BCG is characterized by metabolic alterations, and upregula- tion of innate immune receptors with BCG-induced trained-im- mune responses in humans noted for upto 3-12 months. ^{28,28,36,37-41} Studies utilising animal models indicate an enhanced protection from viruses including herpes simplex, influenza A, vaccinia, and Japanese encephalitis infection, following BCG vaccination.³⁴

A study examining adults aged 35–41 years suggested that BCG vaccination during childhood was associated with a similar rate of positive SARS-CoV-2 test rates compared with no vaccination indicating that the BCG vaccine may not reduce the likelihood of acquiring the virus.⁴² However, a retrospective cohort study ex- amining individuals 18 or older in the USA found that COVID-19 patients with BCG vaccination were less likely to require hospital admission, perhaps suggesting a potential effect in preventing severe symptoms rather than preventing infection.^23,43,44

OPV applications for COVID-19

The OPV consists of live attenuated polioviruses, administration of which not only seemed to result in protection from poliomy- elitis, but also seemed to reduce the number of other viruses isolated from immunized children, with the most plausible ex- planation proposed being viral interference mediated by innate immunity.^45,46 Further studies indicated that OPV administration was effective against influenza infection in reducing morbidity, and a therapeutic effect on genital herpes simplex virus infec- tions. OPV also demosntrated oncolytic properties, both by di- rectly destroying tumor cells and by activating cellular immuni- ty toward tumors.^47,48,49

Indeed, mass immunization with OPV helped to control an out- break of unrelated acute poliomyelitis-like disease caused by En- terovirus 71 in Bulgaria.47 Furthermore, OPV reduced the burden of bacterial diarrheal disease in infants, and was associated with decreased middle ear infections which can be caused by both vi- ruses and bacteria.^50,51 Furthermore, OPV usage also seemed as- sociated with reduced hospital admissions for respiratory infec- tions in children.⁴⁶ Perhaps OPV ameliorates/prevents COVID-19 as both the poliovirus and coronavirus are positive-strand RNA viruses and may be governed by common innate immunity mechanisms. Such data, coupled with a recorded safety, more than one serotype to sequentially prolong protection, low cost and ease of administration, and availability, could indicate the supreme usefulness of OPV in the fight against SARS-CoV-2 and COVID-19.^46,48,49 Indeed, OPV seems safer compared to BCG, with ~1% of BCG recipients exhibiting adverse reactions requir- ing medical attention, while such risks are relatively rarely asso- ciated with OPV.⁴⁶

Non-specific effects of live-attenuated vaccines may prove useful in COVID-19 treatment and spread prevention

Considering the collective evidence, there is substantial ground to test NSE of vaccines such as BCG, OPV and measles-contain- ing vaccines in combating the current challenges of the pandem- ic. Ideally, an antiviral vaccine should reduce the likelihood of severe illness and hospitalisation, and interrupt further disease transmission. However, the current trials underlying the most promising candidates do not seem designed to detect a reduc- tion in any of these criteria.⁵² Furthermore, Pfizer and Moderna collectively estimate availability of enough doses for ~35 million individuals in 2020, reaching ~1 billion by 2021, indicating that millions of high risk individuals will not gain access to vaccines any time soon.⁵³

Even if one does not consider the considerable logistical chal- lenges of manufacturing and distributing successful vaccine candidates, equitable access is still an unaddressed issue. While COVAX, a financing mechanism intended to provide COVID vaccines to low and middle-income countries has raised US$ 2 billion, it still requires another $ 5 billion to meet its targets in 2021. Furthermore, Pfizer and Moderna have not yet reached agreements with COVAX to supply vaccines, while a handful of high-income countries have already bought hundreds of millions of doses. Indeed, profit limitation does not seem a priority area for most vaccine producers.⁵³ To this degree, utilisation of exist- ing, and perhaps more reliable resources would benefit a maxi- mal number of people compared to only a ‘new vaccine’-centric approach. However, perhaps a more pertinent point to consider is that it remains likely that vaccines will perhaps be just one determinant affecting our responses to the ongoing pandemic. The sheer number of unknowns regarding the current crisis is astounding; the nature and length of immune responses, pos- sibility/severity of reinfection following vaccination, immunity variation in gender ethnicity and age, the possibility of seasonal outbreaks and viral re-emergence.⁵⁴

Acknowledgements

The manuscript was conceived by AY and JK, and all authors contributed towards writing the manuscript, which was submit- ted following approval of all authors. This work was supported by a COVID-19 project grant (#951) awarded by the Saudi Arabi- an Ministry of Health awarded to AY, JK and KK.

Conflict of Interest Statement

The authors report no conflict of interest.

References

1. Hui DS. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020; 91:264-266.
2. Wang W, J Tang, F Wei. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol. 2020; 92(4):441-447.
3. Zhu N. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733.
4. Chen N. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223): 507-513.
5. Galluccio F. Treatment algorithm for COVID-19: A multidisciplinary point of view. Clin Rheumatol. 2020; 39(7): 2077-2084.
6. Azkur AK. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020; 75(7): 1564-1581.
7. Koirala A. Vaccines for COVID-19: The current state of play. Paediatr Respir Rev. 2020; 35: 43-49.
8. Organisation WH. Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update. 2020;
9. Williamson EJ. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020; 584(7821): 430-436.
10. Heaton PM. The Covid-19 vaccine-development multiverse. N Engl J Med. 2020; 383(20): 1986-1988.
11. Organistion WH. Draft landscape of COVID-19 candidate vaccines. 2020 [cited 2020 22 November 2020]
12. Jeyanathan M. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020; 20(10): 615-632.
13. Martin JE. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine. 2008; 26(50): 6338-43.
14. Folegatti PM. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: A dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect Dis. 2020; 20(7):816-826.
15. Fuller DH, P Berglund. Amplifying RNA vaccine development. N Engl J Med. 2020; 382(25): 2469-2471.
16. Knobler SL, MA, Pray LA. Institute of Medicine (US) Forum on Emerging Infections. Chapter 3: Vaccines: Research, Development, Production, and Procurement Issues. Biological Threats and Terrorism: Assessing The Science and Response Capabilities: Workshop Summary., ed. M.A. Knobler SL, Pray LA. 2002, Washington (DC): National Academies Press (US).
17. Caddy S. Developing a vaccine for covid-19. e British Med j. 2020; 369: m1790.
18. Jackson LA. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med. 2020; 383(20): 1920-1931.
19. Poland GA, IG Ovsyannikova, RB Kennedy. SARS-CoV-2 immunity: Review and applications to phase 3 vaccine candidates. Lancet. 2020; 396(10262): 1595-1606.
20. Kremer EJ. Pros and cons of adenovirus-based SARS-CoV-2 vaccines. Mol Ther. 2020; 28(11): 2303-2304.
21. Ng W, X Liu, S Mahalingam. Development of vaccines for SARS-CoV-2 [version 1; peer review: 2 approved]. F1000Research. 2020; 9(991).
22. Flanagan KL. Progress and pitfalls in the quest for effective SARS-CoV-2 (COVID-19) vaccines. Frontiers in Immunology. 2020; 11(2410).
23. Dockrell HM, SG Smith. What have we learnt about BCG vaccination in the last 20 years? Front Immunol. 2017; 8:1134.
24. Escobar LE, A Molina-Cruz, C Barillas-Mury. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci USA. 2020; 117(30): 17720-17726.
25. Abbas AM. The effect of BCG vaccine in the era of COVID-19 pandemic. Scand J Immunol. 2020: e12947.
26. Eckl-Dorna J, FD Batista. BCR-mediated uptake of antigen linked to TLR9 ligand stimulates B-cell proliferation and antigen-specific plasma cell formation. Blood. 2009; 113(17): 3969-77.
27. Tielemans S. Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands. British Med j. 2017; 358: j3862.
28. Uthayakumar D. Non-specific Effects of vaccines illustrated through the BCG example: from observations to demonstrations. Front Immunol. 2018; 9: 2869.
29. Project BH. OPV as potential protection against COVID-19 (clinicaltrials.gov identifier: NCT04445428). [Online] 2020 [cited 2020 22 November 2020];
30. Fidel PL, Jr MC Noverr. Could an unrelated live attenuated vaccine serve as a preventive measure to dampen septic inflammation associated with COVID-19 infection? mBio. 2020; 11(3).
31. Shelly A. Impact of microbiota: A paradigm for evolving herd immunity against viral diseases. Viruses. 2020; 12(10): 1150.
32. Vita R. The immune epitope database (IEDB): 2018 update. Nucleic Acids Res. 2019; 47(D1): D339-d343.
33. Altschul SF. Basic local alignment search tool. J Molecular Bio. 1990; 215(3): 403-410.
34. Moorlag S. Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect. 2019; 25(12): 1473-1478.
35. Gopalaswamy R. The strange case of BCG and COVID-19: The verdict is still up in the air. Vaccines (Basel), 2020. 8(4):612.
36. Rusek P. Infectious agents as stimuli of trained innate immunity. Int J Mol Sci. 2018; 19(2).
37. Butkeviciute E, CE Jones, SG Smith. Heterologous effects of infant BCG vaccination: Potential mechanisms of immunity. Future Microbiol. 2018; 13(10): 1193-1208.
38. Kleinnijenhuis J, R van Crevel, MG Netea. Trained immunity: Consequences for the heterologous effects of BCG vaccination. Trans R Soc Trop Med Hyg. 2015; 109(1): 29-35.
39. Netea MG, R van Crevel. BCG-induced protection: effects on innate immune memory.  Semin Immunol, 2014; 26(6): 512-7.
40. Netea MG. Trained Immunity: A tool for reducing susceptibility to and the severity of SARS-CoV-2 infection. Cell. 2020; 181(5): 969-977.
41. Kleinnijenhuis J. Bacille calmette-guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci USA, 2012. 109(43):17537-42.
42. Hamiel U, E Kozer, I Youngster. SARS-CoV-2 rates in BCG-vaccinated and unvaccinated young adults. Jama. 2020; 323(22): 2340-2341.
43. Weng CH. Bacillus calmette-guérin vaccination and clinical characteristics and outcomes of COVID-19 in Rhode Island, United States: A cohort study. Epidemiol Infect. 2020; 148: e140.
44. Weng CH, PA Chan. BCG as an adjunct or alternative vaccine to prevent COVID-19? J Travel Med. 2020; 27(7).
45. Hale JH. Large-scale use of Sabin type 2 attenuated poliovirus vaccine in singapore during a type 1 poliomyelitis epidemic. British Medi J. 1959; 1(5137): 1541-1549.
46. Chumakov K. Can existing live vaccines prevent COVID-19? Science. 2020; 368(6496): 1187-1188.
47. Shindarov LM. Epidemiological, clinical, and pathomorphological characteristics of epidemic poliomyelitis-like disease caused by enterovirus 71. J Hyg Epidemiol Microbiol Immunol. 1979; 23(3): 284-95.
48. Chumakov MP. Live enteroviral vaccines for the emergency nonspecific prevention of mass respiratory diseases during fall-winter epidemics of influenza and acute respiratory diseases. Zh Mikrobiol Epidemiol Immunobiol. 1992(11-12): 37-40.
49. Voroshilova MK. Potential use of nonpathogenic enteroviruses for control of human disease. Prog Med Virol. 1989; 36: 191-202.
50. Upfill-Brown A. Nonspecific effects of oral polio vaccine on diarrheal burden and etiology among bangladeshi infants. Clin Infect Dis. 2017; 65(3): 414-419.
51. Seppälä E. Viral interference induced by live attenuated virus vaccine (OPV) can prevent otitis media. Vaccine. 2011; 29(47): 8615-8.
52. Doshi P. Will covid-19 vaccines save lives? Current trials aren't designed to tell us. Bmj. 2020; 371: m4037.
53. The L. COVID-19 vaccines: No time for complacency. Lancet. 2020; 396(10263): 1607.
54. Funk CD, C Laferrière, A Ardakani. A snapshot of the global race for vaccines targeting SARS-CoV-2 and the COVID-19 pandemic. Front Pharmacol. 2020; 11: 937.